ADI
57
-6
TDC
62
3
NUE
34
-3
CL
50
-3
LLY
57
-2
V
64
14
EMR
50
2
NKE
31
3
ZBH
50
-3
ROP
51
-2
DLTR
55
3
KEY
60
2
FLS
59
-2
AA
32
-3
FSLR
40
-3
URI
60
2
BLK
58
-2
KSS
41
2
BEN
42
-3
HSIC
51
-3
ADI
57
-6
TDC
62
3
NUE
34
-3
CL
50
-3
LLY
57
-2
V
64
14
EMR
50
2
NKE
31
3
ZBH
50
-3
ROP
51
-2
DLTR
55
3
KEY
60
2
FLS
59
-2
AA
32
-3
FSLR
40
-3
URI
60
2
BLK
58
-2
KSS
41
2
BEN
42
-3
HSIC
51
-3
Financhill
Back

Stoke Therapeutics 10K Form

Sell
28

STOK
Stoke Therapeutics

Last Price:
$9.48
Seasonality Move:
-12.77%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive STOK News And Ratings

See the #1 stock for the next 7 days that we like better than STOK

STOK Financial Statistics

Sales & Book Value

Annual Sales: $36.6M
Cash Flow: $131.7M
Price / Cash Flow: 7.84
Annual Sales: $6.41
Price / Book: 1.48

Profitability

EPS (TTM): 0.79000
Net Income (TTM): $50.3M
Gross Margin: --
Return on Equity: 21.05%
Return on Assets: 16.93%

Stoke Therapeutics Earnings Forecast

Key Stoke Therapeutics Financial Ratios

  • The Research & Development expenses have been 243.83% of Revenue.
  • The Net Earning history of STOK is -243.42% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 3 years.

Stoke Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: STOK
CUSIP: 86150R
Website: stoketherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 8.41
Quick Ratio: 8.01

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

STOK Technical Analysis vs Fundamental Analysis

Sell
28
Stoke Therapeutics (STOK) is a Sell

Is Stoke Therapeutics a Buy or a Sell?